Volition announces two oral presentations at asian meeting of animal medicine specialties

Henderson, nevada , june 4, 2025 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, today announces two oral presentations featuring its nu.q® vet cancer test at the asian meeting of animal medicine specialties (amams 2025), a premier event bringing together leading veterinary professionals and experts from across asia. the two presentations feature results from two clinical studies conducted by dr masahiko sato, dvm, phd, dacvim (saim), daicvim (im) in conjunction with fujifilm vet systems.
VNRX Ratings Summary
VNRX Quant Ranking